What the research says about tesamorelin

What tesamorelin is

Tesamorelin is described in the literature as a synthetic analogue of human growth-hormone-releasing hormone (also called growth-hormone-releasing factor) that stimulates the pituitary to synthesize and release the body's own growth hormone ^[2]. In November 2010 the US Food and Drug Administration approved tesamorelin (marketed as Egrifta) for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy ^[1].

Nearly all of the controlled human research on tesamorelin was done in that specific population. Material sold by third-party research-chemical vendors is not the approved pharmacy product and is offered for laboratory and research use only.

What the human research has measured

In two 26-week, double-blind, placebo-controlled phase 3 trials in people with HIV-associated central fat accumulation, subcutaneous tesamorelin reduced visceral adipose tissue while not meaningfully changing subcutaneous fat; a pooled analysis reported that visceral fat fell by roughly 15% to 20% over 6 to 12 months ^[2][3]. The reduction was maintained through week 52 in people who continued treatment, but visceral fat reaccumulated after tesamorelin was stopped ^[2].

A separate randomized, double-blind trial in 61 people with HIV and non-alcoholic fatty liver disease reported an absolute reduction in hepatic fat fraction of about -4.1% versus placebo (about a -37% relative reduction), and that 35% of the tesamorelin group versus 4% of placebo reached a hepatic fat fraction below 5% ^[4]. Paired liver-biopsy analysis from that trial reported shifts in hepatic gene expression consistent with reduced inflammation and fibrosis signaling ^[5].

A 2026 systematic review and meta-analysis pooled 5 randomized controlled trials ^[6]. It reported significant reductions versus placebo in visceral adipose tissue (mean difference about -27.71 cm²), trunk fat (about -1.18 kg), hepatic fat (about -4.28%), and waist circumference (about -1.61 cm), and an increase in lean body mass (about 1.42 kg), with no significant change in subcutaneous fat or overall BMI ^[6]. A 2024 trial reported similar liver- and visceral-fat benefits among participants on modern integrase-inhibitor HIV regimens ^[7].

What the trials report on safety and adverse events

The tesamorelin trials measured adverse events alongside body-composition outcomes. A 2011 review reported that treatment-emergent serious adverse events occurred in fewer than 4% of patients over 26 weeks of therapy, and that most events were injection-site reactions or effects known to accompany growth-hormone therapy, such as arthralgia, headache, and peripheral edema ^[2].

The 2026 meta-analysis reported adverse events including arthralgia, myalgia, paresthesia, and injection-site reactions such as erythema, while reporting no significant perturbation of glucose control and no significant change in CD4+ T-cell counts ^[6]. In the HIV-and-NAFLD trial, changes in fasting glucose and glycated hemoglobin were not different between groups at 12 months, and localized injection-site complaints were more frequent on tesamorelin ^[4].

A 6-month phase 2 trial testing whether tesamorelin could improve neurocognition in people with HIV and abdominal obesity reported a greater reduction in waist circumference (median difference about -2.7 cm) but no significant cognitive benefit versus standard of care, and the authors noted the study was underpowered and lacked a placebo arm ^[8].

These are measured rates within controlled trials of an approved, pharmaceutical-grade medicine studied in a specific patient population, not a safety guarantee and not a prediction for any individual. Material sold by research-chemical vendors is not that regulated product. This is not medical advice; consult a qualified professional and read the trials directly.

How strong is the evidence

Because tesamorelin's effects have been measured in multiple randomized, placebo-controlled trials and pooled in a meta-analysis, the evidence base is characterized as strong relative to the preclinical-only peptides in this library ^[6][3]. "Strong" describes the quality and design of the published trials, not an endorsement, and it is important to note the scope: almost all of this evidence is in people with HIV-associated lipodystrophy, not the general population ^[1][2].

Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.